An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT00425854
- Locations
- 🇩🇪
1200.10.49006 Boehringer Ingelheim Investigational Site, Wiesbaden, Germany
🇧🇪1200.10.3204 Boehringer Ingelheim Investigational Site, Leuven, Belgium
🇩🇪1200.10.49003 Boehringer Ingelheim Investigational Site, Kiel, Germany
Effect of BIBW 2948 BS in COPD
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT00423137
- Locations
- 🇺🇸
1219.5.01 Boehringer Ingelheim Investigational Site, San Francisco, California, United States
🇩🇪1219.5.06 Boehringer Ingelheim Investigational Site, Freiburg/Breisgau, Germany
🇺🇸1219.5.04 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
BI 2536 Second Line Monotherapy in SCLC
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT00412880
- Locations
- 🇺🇸
1216.11.003 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸1216.11.006 Boehringer Ingelheim Investigational Site, Evanston, Illinois, United States
🇨🇦1216.11.009 Alberta Cancer Board, Edmonton, Alberta, Canada
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 312
- Registration Number
- NCT00402233
- Locations
- 🇺🇸
248.622.5 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸248.622.40 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States
🇺🇸248.622.76 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1480
- Registration Number
- NCT00400153
- Locations
- 🇺🇸
1012.56.01014 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸1012.56.01043 Boehringer Ingelheim Investigational Site, Palo Alto, California, United States
🇺🇸1012.56.01036 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States
A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.
- Conditions
- Interventions
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 154
- Registration Number
- NCT00390689
- Locations
- 🇯🇵
248.627.031 Boehringer Ingelheim Investigational Site, Urasoe, Okinawa, Japan
🇯🇵248.627.037 Boehringer Ingelheim Investigational Site, Aichi-gun, Aichi, Japan
🇯🇵248.627.023 Boehringer Ingelheim Investigational Site, Kitakyusyu, Fukuoka, Japan
Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
- Conditions
- Interventions
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 576
- Registration Number
- NCT00389207
- Locations
- 🇲🇽
1100.1470.55001 Boehringer Ingelheim Investigational Site, Col. Toriello Guerra, Mexico
🇵🇹1100.1470.35103 Boehringer Ingelheim Investigational Site, Porto, Portugal
🇨🇭1100.1470.41002 Boehringer Ingelheim Investigational Site, Zürich, Switzerland
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
- Conditions
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 327
- Registration Number
- NCT00388882
- Locations
- 🇺🇸
205.346.105 Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States
🇦🇷205.346.509, Rosario, Santa Fe, Argentina
🇦🇷205.346.511, Rosario, Santa Fé, Argentina
Tiotropium / Respimat One Year Study in COPD.
- Conditions
- Interventions
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3991
- Registration Number
- NCT00387088
- Locations
- 🇺🇸
205.372.01028 Boehringer Ingelheim Investigational Site, Rancho Mirage, California, United States
🇺🇸205.372.01060 Boehringer Ingelheim Investigational Site, Clearwater, Florida, United States
🇺🇸205.372.01008 Boehringer Ingelheim Investigational Site, Norwalk, Connecticut, United States
Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT00376623
- Locations
- 🇩🇪
1216.9.49001 Boehringer Ingelheim Investigational Site, Heidelberg, Germany
🇩🇪1216.9.49002 Boehringer Ingelheim Investigational Site, Freiburg, Germany
🇩🇪1216.9.49007 Boehringer Ingelheim Investigational Site, Gauting, Germany